(NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...

Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.

Shares of bluebird bio (NASDAQ:BLUE) continued their downward descent Monday in the wake of news that the company has been agreed to be taken private by Carlyle Group (NASDAQ:CG) and SK Capital ...

Mirum Pharmaceuticals (MIRM) announced that the FDA has approved Ctexli tablets, a bile acid, for the treatment of adults with cerebrotendinous ...

Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with ...

An approval for the first drug for a rare lipid storage disease, some FDA workers rehired, and other biotech news of the day ...

A young Peninsula drugmaker won regulatory approval Friday for a rare-disease drug picked up in a deal two years ago.